SGLT2 inhibitors improve plasma atherogenic biomarkers in patients with type 2 diabetes: a real world retrospective observational study.


Imre E., Gunhan H. G., Erel P., Ustay Ö.

Minerva endocrinology, 2021 (Hakemli Dergi) identifier